Introduction Incidence of urethral stricture recurrence ranges between 2% to 36.4% with 75% occurring within the first 6 months of surgery. Hence, they need to identify the predictors of recurrence following urethroplasty. Methods This is a retrospective study involving patients that had urethroplasty from January 2008 to December 2017. Patients' records were reviewed. Analyzed data were for patients with a minimum follow up of one year from the time of urethroplasty and included aetiology of urethral stricture, presence of suprapubic cystostomy, prior urethral dilatation, urine M/C/S, site of urethral stricture, length of urethral stricture, type of urethroplasty, level of training of the surgeon, type of urethral stent used and duration of stenting. Analysis was done using SPSS version 23. P-value of < 0.05 was considered significant. Results Eighty seven urethroplasties were done, from January 2008 to December 2017. However, only records of 44 patients were accessible. Twenty patients completed duration of follow up ≥ one year. Urethral stricture recurrence was defined as resurgence of Lower Urinary Tract Symptoms (LUTS) within one year. Median age of the patients was 39.5 (± 19) years. Urethral stricture recurrence rate was 25% with mean time to recurrence from urethroplasty of 5.3 (±3) months. The use of preoperative suprapubic catheter (SPC) for urinary diversion as well as urethroplasties performed by the consultants had a lower incidence of recurrence. Conclusion This study found urethral stricture recurrence of 25%. The level of training of surgeon vis-à-vis the expertise and experience seems to be an important factor, though not statistically significant in determining the outcome of urethroplasty.
Aims:To determine the presentation, characteristics and associated co-morbidities in Nigerian men with prostate cancer. Methodology: Men with histologically confirmed prostate cancer were analyzed. The age of the men, PSA pattern, histologic type, Gleason score, stage of the disease, associated co-morbidities and treatment received by the men were recorded. The effect of co-morbidities on disease aggressiveness using Gleason score and PSA as determinants was determined using Pearson correlation. SPSS version 23 was used in analyzing the data. P-value of < 0.05 was considered significant. Results: Eighty-one patients with prostate cancer from 2010 to 2018 were involved in the study. The mean age was 67.58±9.42 years with a range of 42 to 96years. Men with PSA >100 ng/ml had the highest frequency (34.60%). The mean Gleason Score was 6.28±2.13. Gleason score 7-8 had the highest frequency (35.8%). Seventy-nine patients (97.5%) had adenocarcinoma. Eighty- Ofoha and Magnus; JAMMR, 31(5): 1-7, 2019; Article no.JAMMR.52918 2 one percent of the men had advanced Pca, 58% being metastatic disease. 48.1% had comorbidities, 39.5% had hypertension, while 8.6% had both hypertension and diabetes. Comorbidities showed no correlation with PSA level (r=0.346), (p-value 0.375) and Gleason score (r=0.194), (p-value 0.639). Seventy-nine percent of the men had androgen deprivation therapy. Conclusion: Most of the men presented with advanced disease, with all indices pointing towards lethal disease. The commonest co-morbidity was hypertension and co-morbidities had no relationship with the aggressiveness of prostate cancer. To ensure early presentation and prevent lethal forms of Pca, health education, screening, counselling for men in the high-risk group is paramount. Original Research Article
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.